Dosage Protocols
Since KPV is not FDA-approved for human use, there are no officially established dosing guidelines. The following information reflects dosages reported in research literature and community use.
Subcutaneous Injection:
- Low dose: 100 to 200 mcg per day
- Standard dose: 200 to 500 mcg per day
- Typical cycle: 4 to 8 weeks
Oral Administration:
- Standard dose: 500 to 1,500 mcg per day
- Some protocols use divided dosing (2 times per day)
- Oral administration is preferred for gastrointestinal conditions due to PepT1-mediated uptake
Topical Application:
- Concentrations and protocols vary; limited standardization exists
- Typically formulated in creams or gels for localized skin conditions
Weight-Based Dosing: Human equivalent doses have not been formally established. Animal study doses cannot be directly extrapolated, and the optimal human dose likely varies by condition and administration route.
Cycling Guidelines:
- Common cycle length: 4 to 8 weeks
- Some users employ continuous low-dose protocols for chronic inflammatory conditions
- Cycling off periodically (2 to 4 weeks) is practiced by some to avoid potential tolerance